Highlights
- •In the sixth month after the first dose, patients with a positive serological status were 86.3%.
- •IgG titer was inferior in patients than in healthcare workers due to a more rapid decline.
- •The estimated time to reach negative serological status was 11.3 months for patients.
Abstract
Introduction
We previously reported on the immunogenicity and safety of BNT162b2 in a large cohort
of patients with cancer after the first and second doses (Di Noia et al., 2021) [1].
Herein, we present result after six months of follow-up.
Methods
This prospective study included patients affected by solid tumors and afferent to
our institution who received two doses of BNT162b2 vaccine. A cohort of vaccinated
healthcare workers (HCW) was used as control-group. Both cohorts were evaluated for
the titer of anti-Spike (S) IgG at prefixed time-points (TPs). Time-point 4 was scheduled
at 24–26 weeks after the second dose.
Results
In the current analysis, 400 patients and 232 healthcare workers were evaluated. Responders
(IgG > 15 AU/mL) in patients group were 86.5% compared with 94.4% among healthcare
workers. Also the IgG titer at TP4 was significantly inferior in patients than in
healthcare workers (70.81 vs 134.64 AU/ml, p < 0.001). There was a more rapid decline
of the antibody level from TP3 to TP4 in patients than in healthcare workers (1.78
vs 1.3 fold). The estimated IgG half-life was significantly shorter for patients (73
days) than in healthcare workers (118 days) as well as the time to reach negative
serological status (340 vs 532 days).
Conclusion
The decline of humoral response to the vaccine observed in patients with solid cancer
after six months from the first dose support the urgent need of an early additional
dose.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution.Clin Cancer Res. 2021; 2439 (2021 Sep 28;clincanres. [Online ahead of print])https://doi.org/10.1158/1078-0432.CCR-21-2439
- Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.Ann Oncol Nov. 2021; 29 ([Online ahead of print])https://doi.org/10.1016/j.annonc.2021.11.015
- SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.Science. 2021; https://doi.org/10.1126/science.abm0620
- The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey.Eur J Cancer. 2021 Aug; 153: 260-264https://doi.org/10.1016/j.ejca.2021.05.006
Article info
Publication history
Published online: March 01, 2022
Accepted:
January 7,
2022
Received:
December 26,
2021
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?European Journal of CancerVol. 176
- PreviewWe had previously reported on the immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Tozinameran) in a large cohort of patients with cancer after the first and the second doses [1], and we subsequently showed the rapid decline of humoral response over the time until 6 months of follow-up [2,3]. We have also recently reported on the potentiation of humoral response after the third dose in this frail population [4], in line with other studies [5–9].
- Full-Text
- Preview
